Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis - 29/11/22
Doi : 10.1016/j.jinf.2022.10.012
Huzaifa Ahmad Cheema a, 1, ⁎ 
, Uzair Jafar a, 1, Asmaa Ahmed Elrashedy b, Abia Shahid a, Rehmat Ullah Awan c, Muhammad Ehsan a, Muhammad Ayyan a, Syeda Sahra d
, Uzair Jafar a, 1, Asmaa Ahmed Elrashedy b, Abia Shahid a, Rehmat Ullah Awan c, Muhammad Ehsan a, Muhammad Ayyan a, Syeda Sahra d a Division of Infectious Diseases, Department of Medicine, King Edward Medical University, Nila Gumbad Chowk, Neela Gumbad, Lahore, Punjab 54000, Pakistan
b Faculty of Medicine, Kafr El-Shaikh University, Kafr El-Shaikh, Egypt
c Department of Medicine, Ochsner Rush Medical Center, Meridian, MS, United States
d Department of Infectious Diseases, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
⁎Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Keywords : Fluvoxamine, COVID-19, SARS-CoV-2, SSRIs
Le texte complet de cet article est disponible en PDF.
Plan
© 2022
Publié par Elsevier Masson SAS.
Vol 85 - N° 6
P. 702-769 - décembre 2022 Retour au numéro
Article précédent
- Persistence of monkeypox virus DNA in clinical specimens
- Zhaowan Li, Xin Xin Li, Yueling Chen, Qianqian Ruan, Xiaorong Huang, Guanghu Zhu, Jiufeng Sun
- Host-cell recognition of SARS-CoV-2 spike receptor binding domain from different variants
- Abdo A Elfiky, Ibrahim M Ibrahim, Mohamed N Ibrahim, Wael M Elshemey
Bienvenue sur EM-consulte, la référence des professionnels de santé.